drugset / Trial / NCT00772109

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

NCT00772109 ↗

Phase 3 Completed 4292 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is designed to test lot consistency of three different manufacturing lots and to generate safety and immunogenicity data of the investigational vaccine administered via the ID route. Primary Objective: * To demonstrate lot consistency of the Fluzone ID manufacturing process. * To provide information concerning the immune response of Fluzone ID. Secondary Objectives: Safety * To describe the safety profile of subjects who receive of Fluzone ID.

Timeline

Start
2008-10
Primary completion
2009-05
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Influenza Virus Vaccine USP Trivalent Types A and B Vaccine 0.1 ml Intrathecal
Comparator Influenza Virus Vaccine USP Trivalent Types A and B Vaccine 0.5 ml Intrathecal

Indications